Abstract
There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are ‘at-risk’ of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.
Keywords: Inflammatory bowel disease, Ulcerative Colitis, Surveillance colonoscopy, dysplasia, colorectal cancer, colectomy, Crohn's disease, NSAIDs, Ursodeoxycholic acid, Chromoendoscopy, Narrow-Band Imging, Confocal Endomicroscopy, DALMs
Current Drug Targets
Title: How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Volume: 12 Issue: 10
Author(s): Raja Affendi Raja Ali and Laurence John Egan
Affiliation:
Keywords: Inflammatory bowel disease, Ulcerative Colitis, Surveillance colonoscopy, dysplasia, colorectal cancer, colectomy, Crohn's disease, NSAIDs, Ursodeoxycholic acid, Chromoendoscopy, Narrow-Band Imging, Confocal Endomicroscopy, DALMs
Abstract: There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are ‘at-risk’ of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.
Export Options
About this article
Cite this article as:
Affendi Raja Ali Raja and John Egan Laurence, How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818270
DOI https://dx.doi.org/10.2174/138945011796818270 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents on Regenerative Medicine Aromatase: The Enzyme and Its Inhibition
Anti-Cancer Agents in Medicinal Chemistry Biological Nanofactories: Using Living Forms for Metal Nanoparticle Synthesis
Mini-Reviews in Medicinal Chemistry Editorial
Anti-Cancer Agents in Medicinal Chemistry Opinion Paper: Microfluidics Technique to Revolutionize the Drug Delivery Field: Current Developments and Applications
Current Drug Delivery Role of Progastrins and Gastrins and Their Receptors in GI and Pancreatic Cancers: Targets for Treatment
Current Pharmaceutical Design Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size
Current Drug Delivery EDITORIAL (Thematic Issue: Special Thematic Issuue: Development of Biomarkers in Tumors of Digestive System Part I)
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients
Current Drug Metabolism Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Cancer Stem Cells and Colorectal Cancer: An Overview
Current Topics in Medicinal Chemistry Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism In Silico Design of New B-Raf Kinase Type-II Inhibitors Through Combined Molecular Modeling Studies
Letters in Drug Design & Discovery Synthesis and Evaluation of Anticancer Activity of 5-Ylidene-4- Aminothiazol-2(5H)-one Derivatives
Medicinal Chemistry Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer
Drug Design Reviews - Online (Discontinued) Colorectal Cancer: Causes and Evidence of Chemopreventive Treatments
Current Pharmaceutical Biotechnology